APLEX Bio selected among top 40 nordic life science startups to join NLS 2022
7 sep. 2022
APLEX Bio will be pitching the international investor community at Nordic Life Science Days in Malmö, Sweden alongside 39 other startups.
Breakthrough early detection of Omicron BA.2 in wastewater achieved with hpPCR
13 apr. 2022
APLEX Bio announces it has demonstrated superior performance of multiplexed COVID variant detection in wastewater, including the generally difficult to detect variant BA.2, using its next-generation hpPCR technology. In a study where samples were tracing back to the end of 2021, results showed that BA.2 could be detected at least one week and up to three weeks earlier compared to next-generation sequencing (NGS) analysis. The study also demonstrated how APLEX Bio’s hpPCR enables ultra-sensitivite analysis while retaining specificity with a cost-effective and rapid workflow going from sample to result within 3 hours.
Genomeweb: In-depth feature with CEO Umear Naseem
15 mars 2022
Sweden's Aplex Bio Gearing up to Launch 'Hyperplexed' PCR Platform
APLEX Bio raises 14 MSEK (€1.3M) for development of its next-generation hyperplexed molecular detection technology
11 mars 2022
APLEX Bio announces it has raised 14 MSEK (€1.3M) for developing its massive multiplexing technology that enables detection of more than 100 biomolecules (DNA, RNA, proteins) with single molecule sensitivity in each drop of sample, without the need for sequencing or other complex instrumentation.
APLEX Bio announces breakthrough ultra-sensitive massively multiplexed (hyperplexed) molecular detection technology
2 mars 2022
APLEX Bio develops breakthrough massive multiplexing technology that enables detection of more than 100 biomolecules (DNA, RNA, proteins) with single molecule sensitivity in each drop of sample, without the need for sequencing or other complex instrumentation.